<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33380/2305-2066-2025-14-3-2090</article-id><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-2167</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕТОДЫ АНАЛИЗА ЛЕКАРСТВЕННЫХ СРЕДСТВ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ANALYTICAL METHODS</subject></subj-group></article-categories><title-group><article-title>Разработка и валидация методики количественного определения эзомепразола магния тригидрата в воздухе рабочей зоны методом ВЭЖХ-МС/МС</article-title><trans-title-group xml:lang="en"><trans-title>Development and validation of esomeprazole magnesium trihydrate determination in workplace air using HPLC-MS/MS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2734-5036</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савченко</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Savchenko</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115409, г. Москва, Каширское шоссе, д. 31</p></bio><bio xml:lang="en"><p>31, Kashirskoe shosse, Moscow, 115409</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4322-3568</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жильцов</surname><given-names>П. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhiltcov</surname><given-names>P. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>249039, Калужская область, г. Обнинск, тер. Студгородок, д. 1</p></bio><bio xml:lang="en"><p>1, Studgorodok territory, Kaluga region, Obninsk, 249039</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5498-527X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Картамышев</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kartamyshev</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115419, г. Москва, ул. Орджоникидзе, д. 11, стр. 11</p></bio><bio xml:lang="en"><p>11/11, Ordzhonikidze str., Moscow, 115419</p></bio><email xlink:type="simple">ikartamyshev@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7500-6122</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гуранда</surname><given-names>Д. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Guranda</surname><given-names>D. T.</given-names></name></name-alternatives><bio xml:lang="ru"><p>121596, г. Москва, ул. Горбунова, д. 2, стр. 11</p></bio><bio xml:lang="en"><p>2/11, Gorbunova str., Moscow, 121596</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8710-6291</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никулин</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikulin</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>121596, г. Москва, ул. Горбунова, д. 2, стр. 11</p></bio><bio xml:lang="en"><p>2/11, Gorbunova str., Moscow, 121596</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное автономное образовательное учреждение высшего образования «Национальный исследовательский ядерный университет «МИФИ» (НИЯУ МИФИ)</institution></aff><aff xml:lang="en"><institution>National Research Nuclear University MEPhI</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Обнинский институт атомной энергетики – филиал федерального государственного автономного образовательного учреждения высшего образования «Национальный исследовательский ядерный университет «МИФИ» (ИАТЭ НИЯУ МИФИ)</institution></aff><aff xml:lang="en"><institution>Obninsk Institute for Nuclear Power Engineering, a branch of National Research Nuclear University MEPhI (IATE MEPhI)</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Общество с ограниченной ответственностью «Фармацевтический научный центр «ИННОФАРМАТЕХ»</institution></aff><aff xml:lang="en"><institution>Limited Liability Company "InnoPharmaTech"</institution></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Общество с ограниченной ответственностью «Фарм Иннтех»</institution></aff><aff xml:lang="en"><institution>Limited Liability Company "Farm Innovation Technologies"</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>09</month><year>2025</year></pub-date><volume>14</volume><issue>3</issue><fpage>147</fpage><lpage>159</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Савченко А.Ю., Жильцов П.А., Картамышев И.И., Гуранда Д.Ф., Никулин М.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Савченко А.Ю., Жильцов П.А., Картамышев И.И., Гуранда Д.Ф., Никулин М.В.</copyright-holder><copyright-holder xml:lang="en">Savchenko A.Y., Zhiltcov P.A., Kartamyshev I.I., Guranda D.T., Nikulin M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/2167">https://www.pharmjournal.ru/jour/article/view/2167</self-uri><abstract><sec><title>Введение</title><p>Введение. Эзомепразол, относящийся к ингибиторам протонного насоса, широко применяется для терапии «кислотозависимых» заболеваний верхних отделов желудочно-кишечного тракта. При ингаляционном воздействии относится к веществам первого класса опасности, что обуславливает необходимость контроля его концентрации в воздухе рабочей зоны на фармацевтических предприятиях. Несмотря на наличие в научной литературе методик количественного анализа эзомепразола в разных матрицах, отсутствуют методы для анализа данного вещества в воздухе производственных помещений.</p></sec><sec><title>Цель</title><p>Цель. Разработка методики количественного определения эзомепразола магния тригидрата в воздухе рабочей зоны методом ВЭЖХ-МС/МС.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Пробы воздуха отбирались на мембранные фильтры диаметром 25 мм при 5,0 л/мин. Анализ проводили с использованием стандартных образцов эзомепразола магния тригидрата и карбамазепина. Хроматографическое разделение осуществляли на колонке C18, 100 × 4,6 мм, 2,5 мкм. Детектирование проводилось на масс-селективном детекторе в положительном режиме ионизации с помощью электроспрея путем мониторинга множественных реакций. MRM-переходы: 346,1 → 198,1 m/z (эзомепразол), 237,1 → 194,1 m/z (карбамазепин).</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Методика валидирована по следующим параметрам: пригодность хроматографической системы (число теоретических тарелок N для эзомепразола – не менее 13170, для карбамазепина – не менее 5617), фактор асимметрии пиков (As) для обоих веществ не превышает 1,36 и 1,41 соответственно; предел обнаружения – 17 нг/мл; нижний предел количественного определения – 50 нг/мл; специфичность (интерферирующие пики для эзомепразола – не более 1,2 %, для карбамазепина – не более 0,25 %); линейность в интервале 50–5000 нг/мл (коэффициент детерминации (R2) – не менее 0,9995, точность в интервале от 92,8 до 106,1 % и относительное стандартное отклонение (RSD, %) – не более 4,2 %); внутрилабораторная правильность (точность от 99,6 до 102,2 %), межлабораторная (от 100,5 до 101,6 %); внутрилабораторная прецизионность (RSD не более 4,3 %), межлабораторная (RSD не более 5,8 %). Все параметры валидации соответствуют критериям приемлемости. Кроме того, установлена стабильность эзомепразола магния тригидрата на фильтрах при хранении до трех месяцев.</p></sec><sec><title>Заключение</title><p>Заключение. Разработка и внедрение методики позволили провести количественный анализ эзомепразола в воздухе рабочей зоны и оценить безопасность производственного процесса в соответствии с гигиеническими требованиями.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Esomeprazole is a proton pump inhibitor widely used in the treatment of acid-related diseases of the upper gastrointestinal tract. Upon inhalation exposure, it is classified as a substance of the highest hazard class, which requires monitoring its concentration in the workplace air at pharmaceutical enterprises. Despite the availability of methods for the quantitative analysis of esomeprazole in various matrices in the scientific literature, there are currently no methods for analyzing this substance in workplace or industrial air.</p></sec><sec><title>Aim</title><p>Aim. To develop a method for the quantitative determination of esomeprazole magnesium trihydrate in workplace air using HPLC-MS/MS.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Air samples were collected using membrane filters with a diameter of 25 mm at a flow rate of 5,0 L/min. The analysis was performed using reference standards of esomeprazole magnesium trihydrate and carbamazepine. Chromatographic separation was carried out on a C18 column (2,5 μm, 100 × 4,6 mm). Detection was performed using a mass-selective detector in positive electrospray ionization mode by multiple reaction monitoring. MRM transitions were: 346,1 → 198,1 m/z for esomeprazole and 237,1 → 194,1 m/z for carbamazepine.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. The method was validated according to the following parameters: suitability of the chromatographic system (the number of theoretical plates, N, for esomeprazole is at least 13170 and for carbamazepine, at least 5617), the asymmetry factor (As) for both substances does not exceed 1,36 and 1,41, respectively; limit of detection: 17 ng/mL; lower limit of quantification: 50 ng/mL; specificity (the response of interfering peaks for esomeprazole at most 1,2 % and for carbamazepine at most 0,25 %); linearity in the range of 50–5000 ng/mL (determination coefficient (R2) of at least 0,9995, accuracy from 92,8 to 106,1 %, and relative standard deviation (RSD, %) at most 4,2 %); intralaboratory accuracy (from 99,6 to 102,2 %) and interlaboratory accuracy (from 100,5 to 101,6 %); intralaboratory precision (RSD at most 4,3 %) and interlaboratory precision (RSD at most 5,8 %). All validation parameters met the acceptance criteria. The stability of esomeprazole on filters was confirmed for up to three months of storage.</p></sec><sec><title>Conclusion</title><p>Conclusion. The development and implementation of the method enabled quantitative analysis of esomeprazole in workplace air and the assessment of the safety of the production process in accordance with hygienic requirements.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>эзомепразол</kwd><kwd>воздух рабочей зоны</kwd><kwd>методика анализа</kwd><kwd>валидация</kwd><kwd>стабильность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>esomeprazole</kwd><kwd>workplace air</kwd><kwd>analytical method</kwd><kwd>validation</kwd><kwd>stability</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование финансировалось за счет ООО «АстраЗенека Индастриз».</funding-statement><funding-statement xml:lang="en">The study was funded by LLC "Astrazeneca Industries".</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Каразей Е. А. Ингибиторы протонной помпы в терапии кислотозависимых заболеваний: фокус на Эзомепразол. Медицинские новости. 2015;9:14–19.</mixed-citation><mixed-citation xml:lang="en">Karazei E. A. Proton pump inhibitors in the treatment of acid peptic disorders: focus on Esomeprazole. Meditsinskie novosti. 2015;9:14–19. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Pyo Y.-C., Nguyen T. N., Lee Y.-S., Choi Y.-E., Park J.-S. Design of esomeprazole solid dispersion for improved dissolution and bioavailability using the supercritical anti-solvent technique. Journal of Drug Delivery Science and Technology. 2023;88:104889. DOI: 10.1016/j.jddst.2023.104889.</mixed-citation><mixed-citation xml:lang="en">Pyo Y.-C., Nguyen T. N., Lee Y.-S., Choi Y.-E., Park J.-S. Design of esomeprazole solid dispersion for improved dissolution and bioavailability using the supercritical anti-solvent technique. Journal of Drug Delivery Science and Technology. 2023;88:104889. DOI: 10.1016/j.jddst.2023.104889.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rashid Z., Ranjha N. M., Rashid F., Raza H. Pharmacokinetic evaluation of microgels for targeted and sustained delivery of acid labile active pharmaceutical agent in animal model. Journal of Drug Delivery Science and Technology. 2020;57:101770. DOI: 10.1016/j.jddst.2020.101770.</mixed-citation><mixed-citation xml:lang="en">Rashid Z., Ranjha N. M., Rashid F., Raza H. Pharmacokinetic evaluation of microgels for targeted and sustained delivery of acid labile active pharmaceutical agent in animal model. Journal of Drug Delivery Science and Technology. 2020;57:101770. DOI: 10.1016/j.jddst.2020.101770.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Yoo H. W., Hong S. J., Kim S. H. Helicobacter pylori Treatment and Gastric Cancer Risk After Endoscopic Resection of Dysplasia: A Nationwide Cohort Study. Gastroenterology. 2024;166(2):313-322. DOI: 10.1053/j.gastro.2023.10.013.</mixed-citation><mixed-citation xml:lang="en">Yoo H. W., Hong S. J., Kim S. H. Helicobacter pylori Treatment and Gastric Cancer Risk After Endoscopic Resection of Dysplasia: A Nationwide Cohort Study. Gastroenterology. 2024;166(2):313-322. DOI: 10.1053/j.gastro.2023.10.013.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Pollmann L., Linnemann J., Pollmann N. S., Jürgens C., Schmeding M. Preoperative proton pump inhibitor therapy and anastomotic leak after esophagectomy–a new perspective. Langenbeck’s Archives of Surgery. 2025;410;157. DOI: 10.1007/s00423-025-03727-3.</mixed-citation><mixed-citation xml:lang="en">Pollmann L., Linnemann J., Pollmann N. S., Jürgens C., Schmeding M. Preoperative proton pump inhibitor therapy and anastomotic leak after esophagectomy–a new perspective. Langenbeck’s Archives of Surgery. 2025;410;157. DOI: 10.1007/s00423-025-03727-3.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Юренев Г. Л., Парцваниа-Виноградова Е. В., Лебедева Е. Г., Заборовский А. В., Тарарина Л. А. Возможности S-энантиомера классической молекулы омепразола (эзомепразола) в лечении гастроэзофагеальной рефлюксной болезни. Consilium Medicum. 2016;18(8):27–31.</mixed-citation><mixed-citation xml:lang="en">Yurenev G. L., Partsvania-Vinogradova E. V., Lebedeva E. G., Zaborovskii A. V., Tararina L. A. Features of classical S-enantiomer of omeprazole molecules (esomeprazole) in the treatment of gastroesophageal reflux disease. Consilium Medicum. 2016;18(8):27–31. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Amin K. F. M. Greenness-sustainability metrics for assessment smart-chemometric spectrophotometric strategy for evaluation of the combination of six gastric proton-pump inhibitors with two selected impurities. MethodsX. 2024;12:102670. DOI: 10.1016/j.mex.2024.102670.</mixed-citation><mixed-citation xml:lang="en">Amin K. F. M. Greenness-sustainability metrics for assessment smart-chemometric spectrophotometric strategy for evaluation of the combination of six gastric proton-pump inhibitors with two selected impurities. MethodsX. 2024;12:102670. DOI: 10.1016/j.mex.2024.102670.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Carrouel F., Dziadzko M., Grégoire C., Galinski M., Dussart C., Lvovschi V.-E. Relevance of early management by proton-pump inhibitor in acute upper gastro-intestinal tract disorder: A scoping review. Biomedicine &amp; Pharmacotherapy. 2023;167:115523. DOI: 10.1016/j.biopha.2023.115523.</mixed-citation><mixed-citation xml:lang="en">Carrouel F., Dziadzko M., Grégoire C., Galinski M., Dussart C., Lvovschi V.-E. Relevance of early management by proton-pump inhibitor in acute upper gastro-intestinal tract disorder: A scoping review. Biomedicine &amp; Pharmacotherapy. 2023;167:115523. DOI: 10.1016/j.biopha.2023.115523.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kumar A., Kumar R., Flanagan J., Långström B., Björndahl L., Darreh-Shori T. Esomeprazole reduces sperm motility index by targeting the spermic cholinergic machinery: A mechanistic study for the association between use of proton pump inhibitors and reduced sperm motility index. Biochemical Pharmacology. 2020;182:114212. DOI: 10.1016/j.bcp.2020.114212.</mixed-citation><mixed-citation xml:lang="en">Kumar A., Kumar R., Flanagan J., Långström B., Björndahl L., Darreh-Shori T. Esomeprazole reduces sperm motility index by targeting the spermic cholinergic machinery: A mechanistic study for the association between use of proton pump inhibitors and reduced sperm motility index. Biochemical Pharmacology. 2020;182:114212. DOI: 10.1016/j.bcp.2020.114212.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Helgadóttir H., Lund S. H., Björnsson E., Gizurarson S. S., Waldum H. Sa1208 – Serum Concentration and Pharmacokinetics of Single and Repeated Oral Doses of Esomeprazole and Gastrin Elevation in Healthy Males and Females. Gastroenterology. 2019;156(6);S-308. DOI: 10.1016/s0016-5085(19)37590-0.</mixed-citation><mixed-citation xml:lang="en">Helgadóttir H., Lund S. H., Björnsson E., Gizurarson S. S., Waldum H. Sa1208 – Serum Concentration and Pharmacokinetics of Single and Repeated Oral Doses of Esomeprazole and Gastrin Elevation in Healthy Males and Females. Gastroenterology. 2019;156(6);S-308. DOI: 10.1016/s0016-5085(19)37590-0.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Косман В. М., Карлина М. В., Мазукина Е. В., Глобенко А. А., Джайн Е. А., Макарова М. Н., Макаров В. Г. Изучение безопасности и токсикокинетики препарата эзомепразол в доклинических исследованиях. Безопасность и риск фармакотерапии. 2023;11(2):176–190. DOI: 10.30895/2312-7821-2023-11-2-342.</mixed-citation><mixed-citation xml:lang="en">Kosman V. M., Karlina M. V., Mazukina E. V., Globenko A. A., Jain E. A., Makarova M. N., Makarov V. G. Preclinical evaluation of esomeprazole safety and toxicokinetics. Safety and Risk of Pharmacotherapy. 2023;11(2):176–190. (In Russ.) DOI: 10.30895/2312-7821-2023-11-2-342.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Rao M. N., Krishna K. B. M., Babu B. H. Development and validation of a stability indicating HPLC method for the simultaneous analysis of esomeprazole and itopride in bulk and in capsules. Journal of Applied Pharmaceutical Science. 2016;6(02):072-080. DOI: 10.7324/japs.2016.60210.</mixed-citation><mixed-citation xml:lang="en">Rao M. N., Krishna K. B. M., Babu B. H. Development and validation of a stability indicating HPLC method for the simultaneous analysis of esomeprazole and itopride in bulk and in capsules. Journal of Applied Pharmaceutical Science. 2016;6(02):072-080. DOI: 10.7324/japs.2016.60210.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zanitti L., Ferretti R., Gallinella B., Torre F. L., Sanna M. L., Mosca A., Cirilli R. Direct HPLC enantioseparation of omeprazole and its chiral impurities: Application to the determination of enantiomeric purity of esomeprazole magnesium trihydrate. Journal of pharmaceutical and biomedical analysis. 2010;52(5):665–671. DOI: 10.1016/j.jpba.2010.02.021.</mixed-citation><mixed-citation xml:lang="en">Zanitti L., Ferretti R., Gallinella B., Torre F. L., Sanna M. L., Mosca A., Cirilli R. Direct HPLC enantioseparation of omeprazole and its chiral impurities: Application to the determination of enantiomeric purity of esomeprazole magnesium trihydrate. Journal of pharmaceutical and biomedical analysis. 2010;52(5):665–671. DOI: 10.1016/j.jpba.2010.02.021.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Liu R., Li P., Xiao J., Yin Y., Sun Z., Bi K., Li Q. A fast, sensitive, and high throughput method for the determination of esomeprazole in dog plasma by UHPLC– MS/MS: Application to formulation development of the compound preparation of esomeprazole. Journal of Chromatography B. 2017;1068–1069:352–357. DOI: 10.1016/j.jchromb.2017.11.002.</mixed-citation><mixed-citation xml:lang="en">Liu R., Li P., Xiao J., Yin Y., Sun Z., Bi K., Li Q. A fast, sensitive, and high throughput method for the determination of esomeprazole in dog plasma by UHPLC– MS/MS: Application to formulation development of the compound preparation of esomeprazole. Journal of Chromatography B. 2017;1068–1069:352–357. DOI: 10.1016/j.jchromb.2017.11.002.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lun J., Ma S., Xue M., Zhao P., Song, Y., Guo, X. Simultaneous enantiomeric analysis of five proton-pump inhibitors in soil and sediment using a modified QuEChERS method and chiral high performance liquid chromatography coupled with tandem mass spectrometry. Microchemical Journal. 2021;160:105625. DOI: 10.1016/j.microc.2020.105625.</mixed-citation><mixed-citation xml:lang="en">Lun J., Ma S., Xue M., Zhao P., Song, Y., Guo, X. Simultaneous enantiomeric analysis of five proton-pump inhibitors in soil and sediment using a modified QuEChERS method and chiral high performance liquid chromatography coupled with tandem mass spectrometry. Microchemical Journal. 2021;160:105625. DOI: 10.1016/j.microc.2020.105625.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Пожарнов И. А., Симаков А. С., Шульга Н. А., Савченко А. Ю., Передеряев О. И., Сынкова Л. С., Медведев Ю. В., Фишер Е. Н. Гигиенический мониторинг загрязненности воздуха рабочей зоны твердыми частицами тикагрелора на фармацевтическом предприятии. Разработка и регистрация лекарственных средств. 2022;11(2):153–158. DOI: 10.33380/2305-2066-2022-11-2-153-158.</mixed-citation><mixed-citation xml:lang="en">Pozharnov I. A., Simakov A. S., Shulga N. A., Savchenko A. Yu., Perederyaev O. I., Synkova L. S., Medvedev Yu. V., Fisher E. N. Hygienic monitoring of working area air pollution by particulate matter of ticagrelor in the pharmaceutical factory. Drug development &amp; registration. 2022;11(2):153–158. (In Russ.) DOI: 10.33380/2305-2066-2022-11-2-153-158.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Пожарнов И. А., Симаков А. С., Шатилина А. А., Раменская Г. В. Организация гигиенического мониторинга загрязненности воздуха рабочей зоны твердыми частицами на фармацевтических предприятиях (обзор). Разработка и регистрация лекарственных средств. 2022;11(1):165–173. DOI: 10.33380/2305-2066-2022-11-1-165-173.</mixed-citation><mixed-citation xml:lang="en">Pozharnov I. A., Simakov A. S., Shatilina A. A., Ramenskaya G. V. Organization of hygienic monitoring of working area air pollution by particulates in pharmaceutical industries (review). Drug development &amp; registration. 2022;11(1):165– 173. (In Russ.) DOI: 10.33380/2305-2066-2022-11-1-165-173.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
